头颈癌患者慢性鼻窦炎发病率与风险的荟萃分析
放疗与慢性鼻窦炎风险升高相关(log OR=1.46,95%CI 0.76-2.16),尤其鼻咽癌患者(log OR 1.82 vs 0.52,p=0.01),同步化疗和晚期病变亦增加风险。
要点
- 头颈癌患者慢性鼻窦炎总体汇总发病率为0.37(95%CI 0.27-0.47)。
- 鼻咽癌患者发病率显著高于其他头颈癌(0.45 vs 0.18,p<0.001)。
- 放疗与慢性鼻窦炎风险升高相关,鼻咽癌患者尤著(p=0.01)。
核心结论
- 鼻咽癌、放疗、晚期病变及同步化疗显著增加头颈癌患者慢性鼻窦炎风险,临床应警惕。
主要发现
- 慢性鼻窦炎诊断方法存在显著异质性。
- 所有头颈癌患者慢性鼻窦炎总体汇总发病率为0.37(95%CI 0.27-0.47)。
- 鼻咽癌患者发病率显著更高(0.45 vs 0.18,p<0.001)。
- 上颌窦最常受累,发病率为0.60,其次为筛窦0.45。
- 放疗与慢性鼻窦炎风险升高相关(log OR=1.46,95%CI 0.76-2.16),鼻咽癌患者风险更高(log OR 1.82 vs 0.52,p=0.01);定性综述显示同步化疗和晚期病变亦增加风险。
关键数值与推荐
- 头颈癌患者慢性鼻窦炎总体汇总发病率0.37(95%CI 0.27-0.47)。
- 鼻咽癌与其他头颈癌发病率比较:0.45 vs 0.18,p<0.001。
- 上颌窦受累发病率0.60,筛窦0.45。
- 放疗与慢性鼻窦炎风险log OR=1.46(95%CI 0.76-2.16)。
- 鼻咽癌患者放疗风险log OR 1.82 vs 其他患者0.52,p=0.01。
临床怎么用
- 治疗头颈癌患者时应知晓慢性鼻窦炎风险,尤其鼻咽癌、接受放疗或同步化疗及晚期病变者。
局限性
- 纳入研究间慢性鼻窦炎诊断方法存在显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several studies have described the occurrence of chronic rhinosinusitis (CRS) in adult patients with head and neck cancers (HNC). The goal of this review is to identify the incidence and risk factors for CRS in adult patients with HNC. DATA SOURCES: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials. REVIEW METHODS: A systematic search was performed from inception to July 2025 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Studies that looked at the development of CRS following treatment of HNC were included. RESULTS: Seventeen studies representing a total of 3685 patients were pooled. There was significant heterogeneity in how CRS was diagnosed. The overall pooled incidence of CRS in all HNC patients was 0.37 (95% CI, 0.27-0.47). The incidence was significantly higher in patients with nasopharyngeal cancer (NPC) (0.45 vs. 0.18, p < 0.001). The maxillary sinuses were the most common sinuses involved with an incidence of 0.60 followed by the ethmoid sinuses at 0.45. Radiation therapy was associated with a higher risk of CRS (log OR = 1.46, 95% CI of 0.76, 2.16), especially in patients with NPC (log OR of 1.82 vs. log OR of 0.52, p = 0.01). Qualitative review showed that concurrent chemotherapy and advanced disease stage also increased the risk of CRS. CONCLUSIONS: The presence of NPC, radiation therapy, advanced stage, and concurrent chemotherapy significantly increases the risk of CRS in patients with head and neck cancers. Clinicians should be aware of the risk when treating these patients.
引用
- Dewey J, Majeethia H, Modi K, et al. Incidence and Risks of Chronic Rhinosinusitis in Head and Neck Cancer: A Meta-Analysis. Laryngoscope. 2026. PMID: 41934348. doi:10.1002/lary.70538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。